SEC Form 4 · accession 0000899243-18-029452
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Vladimir Vexler
Officer — Chief Scientific Officer
Period of report
Nov 16, 2018
Accepted (ET)
Nov 20, 2018 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par value | holding | — | — | — | 12,300 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.27 | Nov 16, 2018 | A | 35,000 | A | — | Nov 16, 2028 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from November 16, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.